Biomea Fusion Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Biomea Fusion Stock Summary

Biomea Fusion competes with Edgewise Therapeutics, Werewolf Therapeutics, Cullinan Oncology, Design Therapeutics, and Ikena Oncology. Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.

Biomea Fusion Key Financial Ratios

Biomea Fusion Key Balance Sheet Accounts

Biomea Fusion Key Income Statement Accounts

Biomea Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biomea Fusion's current stock value. Our valuation model uses many indicators to compare Biomea Fusion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomea Fusion competition to find correlations between indicators driving Biomea Fusion's intrinsic value. More Info.Biomea Fusion is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Biomea Fusion's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomea Fusion's earnings, one of the primary drivers of an investment's value.

Biomea Fusion Systematic Risk

Today, most investors in Biomea Fusion Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomea Fusion's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biomea Fusion growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Biomea Fusion help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biomea Fusion. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biomea Fusion based on widely used predictive technical indicators. In general, we focus on analyzing Biomea Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomea Fusion's daily price indicators and compare them against related drivers.

When running Biomea Fusion's price analysis, check to measure Biomea Fusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomea Fusion is operating at the current time. Most of Biomea Fusion's value examination focuses on studying past and present price action to predict the probability of Biomea Fusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomea Fusion's price. Additionally, you may evaluate how the addition of Biomea Fusion to your portfolios can decrease your overall portfolio volatility.